ArticleInternal medicine journal2026
Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGreater insight into the effects of cystic fibrosis (CF) transmembrane modulators such as elexacaftor-tezacaftor-ivacaftor (ETI) on glucose metabolism can support a more dynamic and individualised approach to CF-related dysglycaemia.
aimTo assess changes in glycemia, body weight and pulmonary function in adults with CF with and without cystic fibrosis related diabetes (CFRD) following ETI.
methodsThis single-centre retrospective cohort study included adults with at least one F508del mutation (23 with CFRD, 38 without CFRD). Exploratory outcomes were HbA1c and total daily insulin doses in the CFRD group and glucose and insulin profiles (0-120 min oral glucose tolerance test [OGTT]), HOMA2-derived indices of insulin resistance (IR), secretion (%S), and β-cell function (%B) in the non-CFRD group. Pulmonary function and weight were assessed in both groups.
resultsMean age was 33.8 ± 10.0 years (CFRD) and 32.8 ± 8.8 years (non-CFRD), with median ETI exposure of 12.3 and 13.4 months, respectively. In the CFRD cohort, HbA1c decreased non-significantly (6.6% to 6.1%, p = 0.2) with no significant change in insulin dose (0.28 to 0.20 IU/kg/day, p = 0.1). In non-CFRD participants, ETI significantly reduced 1- and 2-hour OGTT glucose levels (9.6 vs. 9.2 mmol/L at 1 h, p < 0.01; 6.1 vs. 4.8 mmol/L at 2 hours, p = 0.01), with 13/38 participants improving OGTT classification; no progression to CFRD occurred. Lung function improved in both groups.
conclusionsAdults with at least one F508del mutation, ETI was associated with a clinically relevant reduction in HbA1c in those with CFRD and improved glucose tolerance in those without, supporting favourable metabolic effects beyond established respiratory benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.